These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 18585943)

  • 1. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S; Madala KK; Jamil K
    J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.
    Rajasekaran R; Sethumadhavan R
    Appl Biochem Biotechnol; 2010 Mar; 160(6):1723-33. PubMed ID: 19455431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS; Usui T; Nabeyama W; Morita H; Fukuzawa K; Nakamura H
    Org Biomol Chem; 2009 Nov; 7(21):4415-27. PubMed ID: 19830290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.
    Ghosh S; Narla RK; Zheng Y; Liu XP; Jun X; Mao C; Sudbeck EA; Uckun FM
    Anticancer Drug Des; 1999 Oct; 14(5):403-10. PubMed ID: 10766295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
    Kamath S; Buolamwini JK
    J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
    J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.
    Huang Y; Rizzo RC
    Biochemistry; 2012 Mar; 51(12):2390-406. PubMed ID: 22352796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and validation of a RET TK catalytic domain by homology modeling.
    Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
    J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
    Bridges AJ; Zhou H; Cody DR; Rewcastle GW; McMichael A; Showalter HD; Fry DW; Kraker AJ; Denny WA
    J Med Chem; 1996 Jan; 39(1):267-76. PubMed ID: 8568816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
    Mukai Y; Shibata H; Nakamura T; Yoshioka Y; Abe Y; Nomura T; Taniai M; Ohta T; Ikemizu S; Nakagawa S; Tsunoda S; Kamada H; Yamagata Y; Tsutsumi Y
    J Mol Biol; 2009 Jan; 385(4):1221-9. PubMed ID: 19084540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
    San Juan AA
    Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
    Zhou Z; Bates M; Madura JD
    Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
    Michalczyk A; Klüter S; Rode HB; Simard JR; Grütter C; Rabiller M; Rauh D
    Bioorg Med Chem; 2008 Apr; 16(7):3482-8. PubMed ID: 18316192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
    Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
    Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
    Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
    J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
    Kitano Y; Suzuki T; Kawahara E; Yamazaki T
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.